PCSK9 Inhibitors

Overview

4.4 out of 5 (20 Reviews)

Credits

1.00

Post Assessment Questions

7

Start Date

1 Jan 2021

Last Review Date

25 Feb 2024

Expiration Date

31 Dec 2023

Estimated Time To Finish

60 Minutes


 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an important regulator of cholesterol metabolism. In the United States, 2 fully humanized monoclonal antibodies—alirocumab and evolocumab— have been approved by the US Food and Drug Administration (FDA) to inhibit or reduce PCSK9 activity. Recently, both the European Union and FDA have approved inclisiran, a small interfering mRNA, that inhibits intracellular PCSK9 synthesis. Increased PCSK9 activity correlates with heightened LDL-C levels, while specific gain-of-function mutations lead to autosomal dominant familial hypercholesterolemia characterized by extremely high total and low-density lipoprotein (LDL) cholesterol levels, premature atherosclerotic vascular disease, and the formation of tendon xanthomas. In most cases, this is due to a genetic mutation of the LDL receptor caused by mutations of the apoprotein B100 or PCSK9 genes. Conversely, individuals with reduced PCSK9 activity, whether due to genetic polymorphism or the administration of PCSK9 monoclonal antibodies, exhibit lower cholesterol levels and a reduced risk of cardiovascular disease. This activity outlines the indications, mechanism of action, administration methods, significant adverse effects, contraindications, monitoring, and toxicity of PCSK9 inhibitors. This activity also helps the interprofessional healthcare team tailor patient therapy for optimal outcomes in serum lipid management and improve cardiovascular outcomes.


Target Audience

This activity has been designed to meet the educational needs of physicians.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Identify patients with familial hypercholesterolemia who may benefit from PCSK9 inhibitor therapy based on their lipid profile and cardiovascular risk factors.

  • Implement evidence-based practices for initiating and titrating PCSK9 inhibitors in eligible patients to achieve optimal low-density lipoprotein cholesterol reduction and cardiovascular risk management.

  • Select appropriate strategies for managing adverse effects and addressing barriers to adherence in patients receiving PCSK9 inhibitors.

  • Collaborate with specialists, clinical pharmacists, and other members of the interprofessional team to optimize patient care and ensure comprehensive management of hypercholesterolemia.

Disclosures

The Campbell University Jerry M. Wallace School of Osteopathic Medicine (CUSOM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they or their immediate family may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CUSOM for resolution, to ensure fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

CUSOM will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for authors, editors, planners, peer reviewers, and/or relevant staff is provided with this activity.

Continuing Education Accreditation Information

 

 

The Campbell University Jerry M. Wallace School of Osteopathic Medicine (CUSOM) is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. CUSOM designates this enduring material for a maximum of 1.00 AOA Category 1 B Credits and will report CME credits commensurate with the extent of the physician's participation in the activity.

Cancellation Policy: Cancellations must be received in writing and a money back guarantee is provided if not completely satisfied.

  • StatPearls and CUSOM reserve the right to cancel any course due to unforeseen circumstances. StatPearls and CUSOM will not be responsible for other expenses incurred by the participant in the unlikely event that the program is canceled.

Equal Opportunity

  • StatPearls and CUSOM are Equal Opportunity / Affirmative Action / Equal Access Institutions. 

Medium or Media Used:

  • Computer Requirements:  Internet Access
  • E-mail Address

Instructions for Credit

  1. Register for the activity and create a StatPearls login.     
  2. Review the required accreditation information:  Target audience, learning objectives and disclosure information.
  3. Complete the entire self-study activity.
  4. Complete the post-test assessments.
  5. Successfully pass the post-test with a minimum score of 100%.
  6. Complete the evaluation form.
  7. Obtain a certificate.

StatPearls and CUSOM adheres to AOA Standards regarding commercial support of continuing medical education. It is the policy of StatPearls and Campbell that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that authors and editors will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation. Detailed disclosure will be made prior to starting the activity.

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

This course is intended for osteopathic physicians who wish to earn AOA CME credit. Take this version of the course to ensure you receive appropriate credit.

 

 
 

Reviews

OSCAR P. on 6/28/2021

Gibi G. on 12/14/2021

Mary Y. on 3/14/2022

thank you

ALI O. on 4/24/2022

K.Navanitha R. on 10/7/2022

christopher k. on 8/19/2022

Carl W. on 8/26/2022

Manish Kumar S. on 9/15/2022

Rayne R. on 12/8/2022

Karl S. on 1/1/2023

John C. on 1/6/2023

Mary C. on 4/22/2023

Arelly J. on 5/28/2023

John P. on 7/18/2023

Sweta S. on 8/27/2023

Feng C. on 12/29/2023

Mary H. on 1/21/2024

Padmini N. on 2/28/2024

Lou Y. on 4/2/2024

Anuradha S. on 4/23/2024

Unlimited Physician CME

Stay up to date on the latest medical knowledge with 6673 CME activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7923.5 hours of CME.

Learn About Lifetime CME

Single Activity

Take this single activity

$39 1 activity

6 Month Unlimited Physician CME

Access to all the Unlimited Physician CME activities in all specialties.

$399 per half year per user

1 Year Unlimited Physician CME

Access to all the Unlimited Physician CME activities in all specialties.

$599 per 1 year per user